Company logo

KRBP - Kiromic BioPharma, Inc.

NASDAQ -> Healthcare -> Biotechnology
Houston, United States
Type: Equity

KRBP price evolution
KRBP
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Current assets
Cash $6.51 $15.12 $25.35 $35.16
Short term investments
Net receivables $0.02 $0.01
Inventory
Total current assets $8.03 $16.73 $27.07 $35.92
Long term investments
Property, plant & equipment $11.46 $9.13 $3.63 $2.58
Goodwill & intangible assets $0.43
Total noncurrent assets $11.49 $9.16 $3.66 $3.04
Total investments
Total assets $19.52 $25.89 $30.73 $38.96
Current liabilities
Accounts payable $4.16 $2.3 $2.21 $0.93
Deferred revenue
Short long term debt $0.65 $0.77 $0.45
Total current liabilities $5.97 $4.11 $3.41 $1.44
Long term debt $1.77 $1.75
Total noncurrent liabilities $1.77 $1.75
Total debt $2.42 $2.51 $0.45
Total liabilities $7.74 $5.86 $3.41 $1.44
Shareholders' equity
Retained earnings -$83.02 -$74.58 -$67.22 -$56.58
Other shareholder equity
Total shareholder equity $11.78 $20.03 $27.32 $37.51
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Current assets
Cash $25.35 $10.15 $1.93
Short term investments
Net receivables $0.02 $0.02
Inventory $0.02
Total current assets $27.07 $10.74 $2.04 $0.56
Long term investments
Property, plant & equipment $3.63 $2.07 $0.59 $0.3
Goodwill & intangible assets
Total noncurrent assets $3.66 $2.09 $0.61
Total investments
Total assets $30.73 $12.83 $2.65 $0.88
Current liabilities
Accounts payable $2.21 $0.67 $0.45 $0.22
Deferred revenue
Short long term debt $0.45 $0.47
Total current liabilities $3.41 $1.47 $0.67 $0.61
Long term debt
Total noncurrent liabilities
Total debt $0.45 $0.47
Total liabilities $3.41 $1.47 $0.67 $0.61
Shareholders' equity
Retained earnings -$67.22 -$41.63 -$22.43 -$18.7
Other shareholder equity
Total shareholder equity $27.32 $11.36 $1.98
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $3.88 $2.93 $3.34 $3.49
Selling, general & administrative $4.55 $4.44 $6.9 $2.66
Total operating expenses $8.43 $7.37 $10.66 $6.14
Operating income -$8.43 -$7.37 -$10.66 -$6.14
Income from continuing operations
EBIT -$8.43 -$7.37 -$10.63 -$6.12
Income tax expense
Interest expense $0 $0 $0.01 $0
Net income
Net income -$8.44 -$7.37 -$10.64 -$6.12
Income (for common shares) -$8.44 -$7.37 -$10.64 -$6.12
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $11.37 $5.05 $1.2
Selling, general & administrative $13.94 $14.14 $2.5
Total operating expenses $25.74 $19.2 $3.68 $3.18
Operating income -$25.74 -$19.2 -$3.68
Income from continuing operations
EBIT -$25.58 -$19.2 -$3.71
Income tax expense
Interest expense $0.01 $0 $0.02 -$0.63
Net income
Net income -$25.59 -$19.2 -$3.73 -$3.82
Income (for common shares) -$25.59 -$19.2 -$3.73
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Net income -$8.44 -$7.37 -$10.64 -$6.12
Operating activities
Depreciation $0.4 $0.18 $0.14 $0.13
Business acquisitions & disposals $0.08
Stock-based compensation $0.18 $0.08 $0.44 $1.11
Total cash flows from operations -$5.97 -$7.58 -$9.17 -$4.81
Investing activities
Capital expenditures -$2.47 -$2.48 -$1.1 -$0.21
Investments
Total cash flows from investing -$2.47 -$2.48 -$1.1 -$0.12
Financing activities
Dividends paid
Sale and purchase of stock $40
Net borrowings -$0.17 -$0.17 $0.45 -$0.09
Total cash flows from financing -$0.17 -$0.17 $0.45 $37.03
Effect of exchange rate
Change in cash and equivalents -$8.61 -$10.23 -$9.81 $32.09
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Net income -$25.59 -$19.2 -$3.73
Operating activities
Depreciation $0.47 $0.2 $0.09
Business acquisitions & disposals $0.08
Stock-based compensation $3.76 $13.25 $0.52
Total cash flows from operations -$20.32 -$6.13 -$2.91
Investing activities
Capital expenditures -$1.89 -$1.46 -$0.3
Investments
Total cash flows from investing -$1.81 -$1.46 -$0.3 -$0.14
Financing activities
Dividends paid
Sale and purchase of stock $40.13 $15 $0.01
Net borrowings $0.09 $0.47 $0.25
Total cash flows from financing $37.34 $15.81 $4.76 $1.63
Effect of exchange rate
Change in cash and equivalents $15.2 $8.22 $1.54 -$0.66
Fundamentals
Market cap $4.31M
Enterprise value $218.44K
Shares outstanding 15.84M
Revenue $0.00
EBITDA -$31.70M
EBIT -$32.55M
Net Income -$32.56M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -0.13
EV/Sales N/A
EV/EBITDA -0.01
EV/EBIT -0.01
P/S ratio N/A
P/B ratio 0.37
Book/Share 0.74
Cash/Share 0.41
EPS -$2.06
ROA -113.17%
ROE -134.77%
Debt/Equity 0.12
Net debt/EBITDA -0.04
Current ratio 1.35
Quick ratio 1.35